|
Alopecia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic prediction of male pattern baldness.
|
28196072 |
2017 |
|
Birth Weight
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors.
|
31043758 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci.
|
25429064 |
2015 |
|
Fetal Membranes, Premature Rupture
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Risk of spontaneous preterm birth and fetal growth associates with fetal SLIT2.
|
31194736 |
2019 |
|
Hair Color
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide study of hair colour in UK Biobank explains most of the SNP heritability.
|
30531825 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.
|
30804561 |
2019 |
|
Lean body mass
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomics of body fat percentage may contribute to sex bias in anorexia nervosa.
|
30593698 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies 112 new loci for body mass index in the Japanese population.
|
28892062 |
2017 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Importantly, 10% of the CCGs are involved in chromatin remodeling, including Arid4b, Kdm6a, and Nsd3, and all SB tumors have at least one mutated gene involved in this process; 20 CCGs, including Ctnnd1, Fbxo11, and Vgll4, are also significantly associated with poor patient survival.
|
22421440 |
2012 |
|
Carcinogenesis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
We also noted that the nonphosphorylatable mutant Vgll4-4A (S58A/S155A/T159A/S280A) suppressed tumorigenesis in pancreatic cancer cells <i>in vitro</i> and <i>in vivo</i> to a greater extent than did wild-type Vgll4, suggesting that mitotic phosphorylation inhibits Vgll4's tumor-suppressive activity.
|
28739871 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Importantly, 10% of the CCGs are involved in chromatin remodeling, including Arid4b, Kdm6a, and Nsd3, and all SB tumors have at least one mutated gene involved in this process; 20 CCGs, including Ctnnd1, Fbxo11, and Vgll4, are also significantly associated with poor patient survival.
|
22421440 |
2012 |
|
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We then explored whether the human orthologs of these genes are associated with schizophrenia in the largest schizophrenia genome-wide association study published to date, and found evidence for association for 4 out of the 20 genes: SF3B1, FOXP1, DLG2 and VGLL4.
|
26460480 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VGLL4 is found to play an important role in several signal pathways, mainly acts as a tumor suppressor interacting with TEADs.
|
30034932 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we identify VGLL4 as a novel tumor suppressor in lung carcinogenesis through negatively regulating the formation of YAP-TEAD complex, the core component of Hpo pathway.
|
24458094 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression of miR-454 may be one of the causes of the downregulation of VGLL4 in TNBC, and VGLL4 acts as a tumor suppressor in TNBC by interacting with STAT3 and subsequently suppresses the STAT3 signaling axis, providing potential biomarkers and therapeutic approaches for this fatal disease.
|
31748508 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
VGLL4 is a member of the Vestigial-like proteins that functions as a tumor suppressor, which directly competes with YAP for binding TEADs in several cancer types.
|
25701461 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Vestigial-Like Family Member 4 (VGLL4) functions as a native inhibitor of cell proliferation and tumor growth through multiple signaling pathways.
|
30119884 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The well-studied oncogenic protein YAP forms a complex with TEAD4 to regulate gene transcription; so does the tumor suppressor VGLL4.
|
28368398 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we found that disruption of Vgll4 results in potent T cell-mediated tumor regression in murine syngeneic models.
|
30396996 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Vgll4 inhibits cell proliferation and tumor growth by competing with YAP for binding to TEA-domain proteins (TEADs).
|
28739871 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results suggest that VGLL4 is a candidate tumor suppressor gene which acts by selectively antagonizing YAP-dependent tumor growth.
|
28733631 |
2017 |